Bristol Myers Squibb stock holds near guidance after Q2 beat
Published on 09/07/2026 at 09:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb (US1078421011) closed at USD 66.78 on September 5, 2026, after a 1.9 percent drop, and the shares traded between USD 66.62 and USD 67.35 that day. MarketBeat says the company just reported Q2 2026 EPS of USD 2.04 on revenue of USD 12.97 billion, both above expectations, with FY 2026 EPS guidance still set at 6.750 to 7.000.
Q2 numbers set the tone
The latest reported quarter gave investors a clean comparison: EPS of USD 2.04 versus USD 1.60 consensus, a USD 0.44 beat, and revenue of USD 12.97 billion versus USD 11.74 billion expected. Revenue was up 5.7 percent year over year, while the same quarter last year produced EPS of USD 1.46.
That is the core read-through for the stock now. The market is balancing a better-than-expected quarter against the fact that the shares still ended below the prior close of USD 68.09 on September 5, 2026.
Guidance and valuation
MarketBeat also cites FY 2026 EPS guidance of USD 6.750 to USD 7.000, and its current consensus view is Moderate Buy with a price target of USD 66.06. On that yardstick, the stock sat slightly above the target after the September 5 close, which leaves little room for a simple multiple rerating story.
The same market snapshot put Bristol Myers Squibb at a market cap of USD 136.56 billion, a P/E ratio of 14.72 and a 52-week range of USD 42.52 to USD 68.64. The shares were only USD 1.86 below the high on September 5, 2026.
Bristol Myers Squibb after the Q2 beat
Key figures point to a quarter that beat estimates, but the stock still trades close to its 52-week high.
Drug portfolio still matters
Bristol Myers Squibb remains a large biopharmaceutical group with a portfolio centered on oncology, immunology and cardiovascular medicines. MarketBeat also points to risks from legacy-drug declines, Eliquis patent expiry and the pause in zola-cel trials, which keeps pipeline execution at the center of the investment case.
For a representative product angle, Eliquis remains one of the key medicines to watch because its future patent profile affects the earnings base that supports guidance.
Stock near the range high
Bristol Myers Squibb stock closed at USD 66.78 on September 5, 2026, on the NYSE, with the session low at USD 66.62 and the high at USD 67.35. The price sat just below the 52-week high of USD 68.64 and well above the 52-week low of USD 42.52.
Bristol Myers Squibb at a glance
- Company: Bristol Myers Squibb Company
- ISIN: US1078421011
- Ticker: BMY
- Trading venue: NYSE
- Price (as of September 5, 2026): USD 66.78
- Market capitalization: USD 136.56 billion
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: S&P 500
